Literature DB >> 22876564

Persistent hyperinsulinemic hypoglycemia of infancy.

Dinesh Yadav1, Bhavna Dhingra, Sandeep Kumar, Virendra Kumar, Ashok Kumar Dutta.   

Abstract

Congenital hyperinsulinism (CHI) is the most frequent cause of severe, persistent hypoglycemia in infancy and childhood. We report a case of CHI with diffuse pancreatic abnormality diagnosed preoperatively using the 68Ga octreotide (DOTA NOC) positron emission tomography scan. Genetic analysis revealed homozygous ABCC8 splicing mutation. Subtotal (95%) pancreatectomy was done, and the infant remained euglycemic and was discharged on breast feeds. The patient is continuously followed up and is asymptomatic until 9 months.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22876564     DOI: 10.1515/jpem-2012-0055

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  4 in total

1.  Could 68Ga-somatostatin analogues be an important alternative to 18F-DOPA PET/CT in pediatrics?

Authors:  Arnoldo Piccardo; Giorgio Treglia
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-27       Impact factor: 9.236

2.  Comment on persistent hyperinsulinemic hypoglycemia of infancy.

Authors:  G P Prashanth; Santosh B Kurbet
Journal:  J Indian Assoc Pediatr Surg       Date:  2013-04

Review 3.  Somatostatin analogues for the treatment of hyperinsulinaemic hypoglycaemia.

Authors:  Basma Haris; Saras Saraswathi; Khalid Hussain
Journal:  Ther Adv Endocrinol Metab       Date:  2020-12-02       Impact factor: 3.565

4.  18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT scans as diagnostic tools in focal congenital hyperinsulinism: a blinded evaluation.

Authors:  Charlotte Dahl Christiansen; Henrik Petersen; Anne Lerberg Nielsen; Sönke Detlefsen; Klaus Brusgaard; Lars Rasmussen; Maria Melikyan; Klas Ekström; Evgenia Globa; Annett Helleskov Rasmussen; Claus Hovendal; Henrik Thybo Christesen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-08       Impact factor: 9.236

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.